The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia

Infection and Immunity

Volumn 79, Issue 7, 2011, Pages 2819-2828

  Kataoka, Kosuke ^a,b,e   Fujihashi, K ^b   Oma, Keita ^d   Fukuyama, Yoshiko ^b   Hollingshead, Susan K ^c   Sekine, Shinichi ^e   Kawabata, Shigetada ^e   Ito, Hiro O ^a   Briles, David E ^c   Oishi, Kazunori ^d  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d OSAKA UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; FLT3 LIGAND; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; PNEUMOCOCCAL SURFACE PROTEIN A VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CERVICAL LYMPH NODE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; FEMALE; IMMUNIZATION; IN VIVO STUDY; INFECTION PREVENTION; LUNG LAVAGE; LYMPHOID TISSUE; MOUSE; NASAL LAVAGE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TARGETING; STREPTOCOCCUS PNEUMONIA; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; EPITHELIAL CELLS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NASAL CAVITY; NASAL MUCOSA; NASAL SPRAYS; PLASMIDS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE; VACCINES, SYNTHETIC;

EID: 79959469884     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01360-10     Document Type: Article

References (42)

1. Bakocevic, N., T. Worbs, A. Davalos-Misslitz, and R. Forster. 2010. T celldendritic cell interaction dynamics during the induction of respiratory tolerance and immunity. J. Immunol. 184:1317-1327.
2. Bogaert, D., R. de Groot, and P. W. M. Hermans. 2004. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect. Dis. 4:144-154.
3. Briles, D. E., et al. 2000. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective adjuvant nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68: 796-800.
4. Briles, D. E., et al. 2000. Immunization of human recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182:1694-1701.
5. Briles, D. E., et al. 1996. Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann. N. Y. Acad. Sci. 797:118-126.
6. Couch, R. B. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350:860-861.
7. + dendritic cells promote protective immunity to respiratory infection with Bordetella pertussis. J. Immunol. 183:400-410.
8. Edwan, J. H., G. Perry, J. E. Talmadge, and D. K. Agrawal. 2004. Flt-3 ligand reverses late allergic response and airway hyper-responsiveness in a mouse model of allergic inflammation. J. Immunol. 172:5016-5023.
9. Fujihashi, K., T. Koga, F. van Ginkel, Y. Hagiwara, and J. R. McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxinbased adjuvants. Vaccine 20:2431-2438.
10. Fujihashi, K., et al. 1996. gamma/delta T cell-deficient mice have impaired mucosal IgA responses. J. Exp. Med. 183:1929-1935.
11. Fukuiwa, T., et al. 2008. A recombination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26:4849-4859.
12. Fukuyama, Y., et al. 2010. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J. Immunol. 185:1755-1762.
13. Gilliland, D. G., and J. D. Griffin. 2002. The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542.
14. Hagiwara, H., et al. 2006. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177:3045-3054.
15. - dendritic cell subsets to prime for eosinophilic airway inflammation in the T-helper type 2-prone milieu of the lung. Clin. Exp. Allergy 34:1834-1840.
16. Imaoka, K., et al. 1998. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55 gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 161:5952-5958.
17. Kataoka, K., and K. Fujihashi. 2009. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev. Vaccines 8:1183-1193.
18. Kataoka, K., et al. 2007. Nasal cholera toxin elicits IL-5 and IL-5 receptor a-chain expressing B-1a B cells for innate mucosal IgA antibody responses. J. Immunol. 178:6058-6065.
19. Kataoka, K., et al. 2004. Nasal Flt3 ligand cDNA elicits CD11c+ CD8+ dendritic cells for enhanced mucosal immunity. J. Immunol. 172:3612-3619.
20. Kurono, Y., et al. 1999. Nasal immunization induces Haemophilus influenzaespecific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J. Infect. Dis. 180:122-132.
21. Kutzler, M. A., and D. B. Weiner. 2004. Developing DNA vaccines that call to dendritic cells. J. Clin. Invest. 114:1241-1244.
22. Langermann, S., S. Palaszynsky, A. Sadzience, C. Stover, and S. Koenig. 1994. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372:552-555.
23. Lewis, D. J. M., et al. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One. 4(9):e6999.
24. Maraskovsky, E., et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-1962.
25. McGhee, J. R., et al. 1992. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75-88.
26. Mestecky, J., R. S. Blumberg, H. Kiyono, and J. R. McGhee. 2003. The mucosal immune system, p. 965-1020. In W. E. Paul, (ed.), Fundamental immunology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
27. Moreno, A. T., et al. 2010. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin. Vaccine Immunol. 17:439- 446.
28. Musher, D. M., A. M. Rueda, M. H. Nahm, E. A. Gravis, and M. C. Rodriguez-Barradas. 2008. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially in adults who have recovered from pneumococcal pneumonia. J. Infect. Dis. 198:1019-1027.
29. Mutsch, M., et al. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903.
30. Ren, B. A., J. Szalai, S. K. Hollingshead, and D. E. Briles. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72:114-122.
31. Roche, A. M., and J. N. Weiser. 2010. Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization. Infect. Immun. 78:2231-2239.
32. Sekine, S., et al. 2008. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J. Immunol. 180:8126-8134.
33. Sen, D., L. Forrest, T. B. Kepler, I. Parker, and M. D. Cahalan. 2010. Selective and site-specific mobilization of dermal dendritic cells and langerhans cells by Th1- and Th2-polarizing adjuvants. Proc. Natl. Acad. Sci. U. S. A. 107:8334-8339.
34. Shao, Z., A. S. Bharadwaj, H. S. McGee, T. L. Makinde, and D. K. Agrawal. 2009. Flt-3 ligand increases a lung dendritic cell subset with regulatory properties in allergic airway inflammation. J. Allergy Clin. Immunol. 123: 917-924.
35. Shao, Z., T. O. Makinde, H. S. McGee, X. Wang, and D. K. Agrawal. 2009. Fms-like tyrosine kinase 3 ligand regulates migratory pattern and antigen uptake of lung dendritic cell subsets in a murine model of allergic airway inflammation. J. Immunol. 183:7531-7538.
36. Takahashi, E., et al. 2010. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 12:778-783.
37. Tart, R. C., L. S. McDaniel, B. A. Ralph, and D. E. Briles. 1996. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J. Infect. Dis. 173:380-386.
38. Triccas, J. A., et al. 2007. Effects of DNA- and Mycobacterium bovis BCGbased delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect. Immun. 75:5368-5375.
39. Vadolas, J., J. K. Davies, P. J. Wright, and R. A. Strugnell. 1995. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 25:969-975.
40. van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165:4778-4782.
41. Vitharsson, G., I. Jonsdottir, S. Jonsson, and H. Valdimarsson. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170:592-599.
42. Wu, H. Y., M. H. Nahm, Y. Guo, M. W. Russell, and D. E. Briles. 1997. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:839-846.